| Item 2.02 | Results of Operations and Financial Condition. |
Salarius Pharmaceuticals, Inc. (the “Company”) has provided preliminary financial results for the quarter ended June 30, 2020, included in Exhibit 99.2 to this Current Report on Form 8-K and incorporated by reference herein.
The information in Item 2.02 of this Current Report on Form 8-K, including the preliminary financial results for the quarter ended June 30, 2020 contained in Exhibit 99.2, shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933 (the “Securities Act”), except as shall be expressly set forth by specific reference in such filing.
| Item 7.01 | Regulation FD Disclosure. |
On July 29, 2020, the Company has made available on its website (www.salariuspharma.com) an investor presentation, which provided information to investors about the Company, a copy of which is furnished herewith as Exhibit 99.3. The information contained in the investor presentation is summary information that is intended to be considered in the context of the Company’s Securities and Exchange Commission (“SEC”) filings and other public announcements that the Company may make, by press release or otherwise, from time to time. All information in Exhibit 99.3 is presented as of the particular date or dates referenced therein, and the Company does not undertake any obligation to, and disclaims any duty to, update any of the information provided therein.
The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.3, shall not be deemed to be filed for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act, except as shall be expressly set forth by specific reference in such filing.
On July 29, 2020, the Company announced that it has commenced an underwritten public offering of its common stock. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
The Company has updated its disclosures. The disclosures are filed herewith as Exhibit 99.2 and are incorporated by reference herein, except for the preliminary financial results for the quarter ended June 30, 2020, which are furnished, and shall not be deemed filed, pursuant to Item 2.02 of this Current Report on Form 8-K.
This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding: the Company’s preliminary estimated financial results; the impact of the COVID-19 pandemic on the Company’s business and the actions it may take in response thereto; the impact of the COVID-19 pandemic on third parties with which the Company works; the Company’s anticipated use of proceeds; the Company’s need for additional financing and expectations as to ability to obtain such financing and the potential impact of any future financing; the Company’s expectations as to funds available under the CPRIT grant; expectations as to the Company’s clinical trials, future operations, and future operating results and expense levels; and the Company’s prospects, plans, and objectives. The Company has based these forward-looking statements on its current expectations and projections about future events and trends that the Company believes may affect its financial condition, results of operations, strategy, short- and long-term business operations and objectives, and financial requirements. In addition, reported results, including preliminary estimated results, should not be considered as an indication of future performance. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those reflected or otherwise implied in such forward-looking statements. These risks and uncertainties include, but are not limited to: the effect of the COVID-19 pandemic on the Company’s business and the success of any measures the Company has taken or may take in the future in response thereto; its ability to manage its business plans, strategies, and outlooks and any business-related forecasts or projections; the availability of sufficient resources to meet its business objectives and operational requirements;
2
